Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.

Sanaz Kamalinia Robert G JossePatrick J DonioLindsay Leduc Baiju R Shah Sheldon W Tobe

Published in: Endocrinology, diabetes & metabolism (2019)

Metformin and the simultaneous initiation of dual therapy, but not AHA used alone or as single add-on combination therapy, was associated with an increased risk of any hypoglycaemia relative to placebo.

Keyphrases

combination therapy
type diabetes
double blind
clinical trial
randomized controlled trial
phase iii
placebo controlled
replacement therapy